Accendra Health, Inc. filed its quarterly report on Form 10-Q with the SEC on November 6, 2026, covering the three and nine months ended September 30, 2026, disclosing continued operating losses and a significant decline in net revenue compared to the prior-year period.

Key Highlights

  • Q3 2026 net revenue: $601,775 thousand, down from $697,264 thousand in Q3 2025, according to the filing.
  • Q3 2026 net loss: $(19,699) thousand, or $(0.25) per basic and diluted share, compared to a net loss of $(150,276) thousand in Q3 2025.
  • Nine-month net loss: $(115,237) thousand, or $(1.50) per basic and diluted share, for the nine months ended September 30, 2026.
  • Cash position: Cash and cash equivalents fell to $26,608 thousand as of September 30, 2026, from $281,989 thousand as of December 31, 2025.
  • Total deficit: The company reported a total deficit of $(568,230) thousand as of September 30, 2026, compared to $(460,978) thousand at December 31, 2025.
  • Loss on debt modification: The filing reported a loss on modification and extinguishment of debt of $17,296 thousand for the nine months ended September 30, 2026.
  • Shares outstanding: 76,924,334 shares of common stock were outstanding as of September 30, 2026.

Accendra Health's Q3 2026 Financial Results: Revenue Decline and Deepening Deficit

Accendra Health, Inc. (NYSE:ACH), a Virginia-incorporated health company headquartered in Glen Allen, Virginia, reported its unaudited condensed consolidated financial results for the three and nine months ended September 30, 2026. According to the filing, net revenue for the third quarter of 2026 was $601,775 thousand, a decline from $697,264 thousand in the same period of 2025. For the nine-month period, net revenue was $1,842,789 thousand, compared to $2,053,065 thousand in the nine months ended September 30, 2025.

The filing disclosed that total operating costs and expenses for Q3 2026 were $600,441 thousand, resulting in operating income of $1,334 thousand for the quarter. However, interest expense, net of $37,621 thousand for the three-month period pushed the company to a loss from continuing operations before income taxes of $(36,819) thousand. After an income tax benefit of $(18,858) thousand, the loss from continuing operations, net of tax, was $(17,961) thousand for Q3 2026. The nine-month loss from continuing operations, net of tax, was $(113,499) thousand, the registrant reported.

On the balance sheet, the company disclosed total assets of $2,078,914 thousand and total liabilities of $2,647,144 thousand as of September 30, 2026, resulting in a total deficit of $(568,230) thousand. The accumulated deficit stood at $(1,194,989) thousand, up from $(1,079,752) thousand at December 31, 2025. Long-term debt, excluding the current portion, was $1,719,966 thousand. For the nine months ended September 30, 2026, the filing also reported a gain from sale of a non-core asset of $32,544 thousand and depreciation and amortization of $166,361 thousand within the cash flow statement.

What Was Disclosed

Accendra Health filed its Form 10-Q for the quarter ended September 30, 2026, disclosing a Q3 net loss of $(19,699) thousand, declining revenues, a sharp drop in cash, and a deepening total deficit, alongside a loss on debt modification of $17,296 thousand for the nine-month period.